ESR1 and triple-negative breast carcinoma: There was a statistically significant higher frequency of ER−, PgR− and HER2-receptor negative patients [triple-negative breast cancer (TNBC)] that succumbed to the disease within 44 months after treatment, compared to ER+, PR+ and HER2− patients (Table I).